Saturday, September 23, 2023
Saturday, September 23, 2023

Synchrony Medical and Sheba Medical Center Initiate 1st Clinical Trial Using a Personalized Chest Physiotherapy System for Patients Living with Chronic Lung Diseases

Synchrony Medical* is a medical device company developing a personalized chest physiotherapy system designed to provide efficient airway clearance. They recently initiated a clinical trial at The National Cystic Fibrosis Center of Israel, at Sheba Medical Center**.

Synchrony Medical notes the trial aims to test the functionality of the system and compare its airway clearance effectiveness to the standard of care solutions currently used in Cystic Fibrosis and Bronchiectasis patients.

“Effective airway clearance on a daily basis at home is the key to keeping chronic lung patients stable and breaking the vicious cycle of clinical deteriorations,” said Dr. Moshe Ashkenazi, Pediatric Pulmonologist, Deputy Director, Safra Children’s Hospital, Sheba Medical Center, and Synchrony Medical’s Co-founder.

Synchrony Medical has developed a novel airway clearance system based on a unique chest physiotherapy method developed at the National Cystic Fibrosis Center of Israel, Sheba Medical Center. The system includes real-time sensing for an adaptive treatment to achieve effective airway clearance.

“Our system will enable patients to receive state-of-the-art chest physiotherapy independently, in the comfort of their own home,” explained Anat Shani, CEO of Synchrony Medical. “By making this effective therapy accessible, Synchrony Medical will bring to patient’s years of experience from Sheba’s respiratory experts and may help minimize pulmonary exacerbations and costly hospitalization associated with chronic lung diseases. This trial brings us one step closer to our goal: improving the lives of millions of chronic lung disease patients who deserve better airway clearance solutions.”

Synchrony Medical is a portfolio company of MEDX Xelerator, a medical device incubator formed as an initiative of MEDX Ventures Group together with Boston Scientific, Intellectual Ventures and Sheba Medical Center.

*Synchrony Medical, a portfolio company of MEDX Xelerator, is a clinical stage medical device company innovating airway clearance for patients living with chronic lung diseases. Synchrony’s system will enable patients to receive high quality chest physiotherapy independently at the comfort of their home.

The system synchronizes a unique chest compression sequence and the delivery of positive airway pressure with the patient’s breathing cycle, according to a personalized treatment algorithm. It is based on a unique airway clearance method developed at the National CF Center of Israel, at the Sheba Medical Center.

**The largest and most comprehensive medical center in the Middle East, Sheba Medical Center, Tel Hashomer is generating global impact through its medical care, research and healthcare transformation. Sheba’s City of Health boasts an acute-care hospital, rehabilitation hospital, research and innovation hubs, medical simulation center and center for disaster response on one comprehensive campus in the center of Israel.

A university teaching hospital affiliated with the Sackler School of Medicine at Tel-Aviv University, Sheba is shaping the future of healthcare, educating the next generation of care providers. Sheba serves as a true hospital without borders, welcoming patients and healthcare professionals from all over the world and consistently providing the highest-level medical care to all in need. Sheba has been ranked a top-ten hospital in the world by Newsweek three years in a row (2019, 2020, 2021).

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

FDA Grants Fast Track Designation to 9MW3011

9MW3011 has been approved to clinical study by NMPA and FDA, respectively. The first person has been dosed in the clinical study in China in March, 2023.

MicuRx receives FDA Qualified Infectious Disease Product (QIDP) and Fast Track Designation for Contezolid and Contezolid acefosamil

"We are pleased to gain the QIDP and Fast Track designations for DFI as recognition that contezolid and contezolid acefosamil are novel new agents to meet an important unmet need in this common and challenging infection", stated Dr Zhengyu Yuan, Chief Executive Officer at MicuRx. 

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) Application for VNT-101

"We look forward to evaluating VNT-101 in the clinic," said Don Ganem MD, Co-Founder and CEO of Via Nova Therapeutics. "This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."

FDA OK’s ensoETM for Use in Cardiac Ablations to Reduce Risk of Esophageal Injury

Published studies that have examined the use of ensoETM for this purpose include the pilot eCOOL-AF study, the IMPACT study and a large multi-center analysis of over 25,000 patients (in press at the Journal of the American College of Cardiology: Clinical Electrophysiology). These studies have found up to an 83 percent reduction in esophageal injuries, and a significant reduction in risk of atrioesophageal fistula (AEF), one of the most dreaded complications of ablation procedures.

Annalise.ai Receives FDA Clearance and Breakthrough Device Designation

Annalise.ai has also received FDA Breakthrough Device Designation for its obstructive hydrocephalus software tool. This is the first radiology triage device to be granted Breakthrough status since the inception of the FDA Breakthrough Devices Program.

By using this website you agree to accept Medical Device News Magazine Privacy Policy